This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Endocyte (ECYT) Slips After Pricing Share Offering

NEW YORK (TheStreet) -- Endocyte (ECYT - Get Report) is sliding on Friday after pricing its previously-announced share offering.

By midafternoon, shares had taken off 7.7% to $21.30. Trading volume of 5.7 million was nearly four times its three-month daily average.

The biopharmaceutical company said it intends to offer 4.5 million shares of common stock at $21 a share, a 9% discount to Thursday's close of $23.07. Endocyte said it had also granted the underwriters a 30-day option to purchase up to an additional 675,000 shares.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Must Read: Why Red Hat (RHT) Is Tumbling on Friday

Before deducting underwriting discounts and commissions, the gross proceeds from the offering will total $94.5 million. Endocyte anticipates redistributing net proceeds to working capital and general corporate purposes, including research and development and capital expenses.

The offering is expected to close around April 2, pursuant to customary closing conditions.

Credit Suisse will act as joint book-running managers, Cowen and Company will serve as lead manager, and RBC Capital Markets, Baird, Wedbush and Roth Capital Partners will act as co-managers.

 Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ECYT $5.19 1.57%
AAPL $113.25 -4.40%
FB $95.00 0.91%
GOOG $629.25 -0.31%
TSLA $263.50 1.40%

Markets

Chart of I:DJI
DOW 17,550.69 -47.51 -0.27%
S&P 500 2,093.32 -4.72 -0.22%
NASDAQ 5,105.5460 -9.8360 -0.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs